Nazli Azimi, Co-Founder and CEORNA as the Operating System of Disease
Every disease process, at some level, involves a breakdown or distortion in how genetic information flows. Biology's information moves from DNA to RNA to protein and RNA sits at the most tractable point in that chain, closer to the root cause than a protein target, yet more chemically approachable than editing DNA itself. This is why RNA-directed therapeutics have quietly become one of the most consequential frontiers in medicine: cancer, genetic disorders, infectious disease, metabolic conditions and neurodegeneration all have an RNA-level entry point, even when the visible symptoms show up elsewhere in the body.
That positioning matters enormously for an industry that has spent a generation searching for "druggable" targets and repeatedly hitting a wall. Traditional small-molecule and antibody approaches can only reach a fraction of the proteins implicated in disease and many targets are considered "undruggable" because they lack the structural pockets or accessible surfaces those approaches require. RNA-targeting and RNA-based therapeutics sidestep much of that limitation. If biology's information truly flows through RNA, then RNA is where a much larger share of disease finally becomes addressable, not hypothetically, but in a way regulators, clinicians and patients have already validated.
A Modality Already Proven, Not Merely Promised
Skeptics of RNA therapeutics used to point out, perhaps reasonably, that the field was long on theory and short on commercial proof. But alas, that argument has expired. mRNA vaccines demonstrated at global scale that RNA-based medicine can be manufactured, distributed and administered to hundreds of millions of people. Antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) therapies have secured regulatory approvals and now generate real revenue from real patients treating real diseases, from rare genetic disorders to chronic conditions previously considered intractable.
This is the part of the story that deserves more attention than it gets: RNA therapeutics are not a speculative technology platform awaiting its first win. It is a validated modality with a track record, an approval pathway and a growing body of clinical and commercial evidence. What has changed recently isn't whether RNA drugs work; it's how fast and how precisely we can design them and that is where artificial intelligence enters the picture as a genuine innovation multiplier rather than a buzzword.
-
RNA isn't just another modality that AI happens to be useful for. It may be the modality where AI's strengths line up most naturally with the underlying biology.
Why RNA Is Uniquely Suited to an AI Revolution
Here is the insight that should reframe how the industry thinks about AI in drug discovery: RNA is, quite literally, a code. It is a linear sequence built from a small, discrete alphabet, with rules governing folding, binding and regulatory function that are learnable from data in a way that is very different from and arguably more tractable than the three-dimensional complexity of protein structures or the combinatorial chemistry space of small molecules.
Large-scale machine learning models thrive on exactly this kind of structured, sequence-based information. The same pattern-recognition capabilities that transformed natural language processing and protein structure prediction are now being turned toward RNA sequence design, secondary and tertiary structure prediction, target identification and delivery optimization. AI models can scan enormous sequence spaces to identify candidate RNA molecules with desired binding or regulatory properties, predict off-target effects before a single molecule reaches the lab bench and compress design cycles that used to take months into days.
In other words, RNA isn't just another modality that AI happens to be useful for. It may be the modality where AI's strengths line up most naturally with the underlying biology. A field built on legible, codeable, information-dense molecules is precisely the kind of problem space where machine learning delivers outsized returns, because the "language" AI needs to learn is the same language the cell already uses to run itself.
The Broader Implication for the Industry
If this thesis holds, it reshapes how investors, drug developers and policymakers should think about where the next decade of pharmaceutical innovation will concentrate. The industry has already lived through eras defined by small molecules, then monoclonal antibodies, then gene therapy's early promise and setbacks. RNA therapeutics, supercharged by AI-native design platforms, represent a plausible next era, not because RNA is fashionable, but because it sits at a genuinely privileged intersection: broad disease relevance, proven clinical viability and a molecular structure uniquely suited to the pattern-recognition strengths of modern AI.
None of this guarantees any individual company's success. Execution, data quality, manufacturing scale-up, delivery technology and regulatory navigation remain the hard, unglamorous work that determines winners from the rest. But the strategic logic of pointing AI at RNA, rather than treating AI as a generic accelerant applied evenly across every modality, is a genuine insight, not just favorable positioning. Biology's information flows through RNA. Increasingly, so will the capital, the talent and the innovation racing to decode it.
Selecting Programmable RNA Therapeutics through Biological Fidelity
A model can generate an RNA sequence quickly and still leave a development team with months of avoidable laboratory work. The cost appears later, when a promising design fails to preserve the intended behavior in the relevant cell type or animal system. RNA function is shaped by sequence context, regulatory architecture, molecular structure and expression kinetics. Buying decisions therefore hinge less on raw generation speed than on whether the platform captures those dependencies before candidate selection.
[QUOTE1_Replace]
Single-property optimization creates a familiar trap. Increasing persistence may alter protein output, while improving expression can weaken tissue restriction. A credible system must reason across linked biological properties rather than optimize one variable in isolation. Executives should examine how the model represents cell context and whether its predictions account for the surrounding transcript environment. A platform built around narrow sequence scoring may produce attractive rankings without explaining why a molecule should perform in a specific tissue.
Training data deserves equal scrutiny. Public datasets are useful for pre-training, but they rarely provide the consistency needed for therapeutic design. Experimental methods, assay conditions, sample handling and biological systems can differ enough to distort model performance. The stronger approach generates proprietary data under controlled conditions, tests predictions in relevant in vitro and in vivo settings, documents failures and returns those findings to the model. This closed loop matters because every failed design should sharpen the next design round rather than remain an isolated laboratory result.
Reported model accuracy can also hide uneven performance across tissues or sequence classes. Review should cover data lineage, assay reproducibility, model versioning and the threshold for moving a design into animal testing. Buyers also need to know whether partner-generated evidence improves future models or remains separated from the core learning system.
Modality coverage requires more than a shared software interface. Designing mRNA therapeutics involves programming durability, tissue restriction, expression level and protein output, while oligonucleotide programs depend on identifying accessible and biologically meaningful regions of a transcript. ASO or siRNA design cannot be reduced to faster tiling. The platform should narrow the search space using cellular context, providing a rationale that experimental teams can test. Buyers should also assess whether the same knowledge base can support distinct therapeutic approaches without forcing them into one generalized model.
Translation speed becomes meaningful only when the platform can move from prediction to a testable molecule through a defined handoff. Internal validation capacity reduces interpretation gaps between computational teams and bench scientists. It also gives management a clearer view of candidate rationale, supporting evidence, remaining uncertainty and the work required before preclinical development. Clear ownership of generated data matters as well, particularly in partnerships where experimental findings may influence later design cycles.
“Therna Biosciences warrants consideration as a premier choice through RNA-Logix, which links RNA foundation models to a proprietary lab-in-theloop system.”
Therna Biosciences warrants consideration as a premier choice through RNA-Logix, which links RNA foundation models to a proprietary lab-in-the-loop system. Experimental data from in-house validation feeds subsequent design cycles, keeping computational output tied to measurable biology. Its logic treats RNA behavior as an interconnected system and supports programmable mRNA medicines and oligonucleotide programs. For ASO and siRNA designs, context-aware prediction can narrow target regions before laboratory testing. Buyers prioritizing biological fidelity, traceable validation, modality-specific design and a shorter route from sequence proposal to tested molecule should view Therna as a focused option.
...Read more
